This article was originally published in The Gray Sheet
"Medical Device Update '98" meeting is planned for June 24-25 in Washington, D.C. Among the topics to be addressed by FDAers are: accelerated approvals and reviews (Susan Alpert, director, ODE); quality system regulation (Kimberly Trautman, Good Manufacturing Practices/Quality Systems Expert, Office of Compliance); international harmonization (Larry Kessler, director, Office of Surveillance and Biometrics); postmarket requirements (Thomas Gross, director, Division of Postmarket Surveillance, OSB); and refurbishers (Casper Uldricks, special assistant to the director, OC). For more information call 1/800-956-6293...
You may also be interested in...
Netherlands' Medicines Evaluation Board says the safety of paracetamol is "not up for debate" after a media investigation reported contamination of the drug with a possible human carcinogen.
There is speculation that it is the end of the road for abicipar pegol but Allergan has declined to say whether this is the case for the product that has been in development for wet AMD.
In the EU, voices calling for a postponement of the IVD Regulation’s 2022 enforcement date are growing louder.